Showing results (81-90 of 90) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
International Journal of Surgery (London, England)|April 4, 2024
Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysisHaoyang Liu, Junru Chen, Yuchen Huang, et al.Annals of Translational Medicine|July 5, 2023
Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancerZhipeng Wang, Haoyang Liu, Jinge Zhao, et al.Annals of Translational Medicine|April 3, 2023
The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancerZhipeng Wang, Haoyang Liu, Jinge Zhao, et al.Asian Journal of Surgery|November 14, 2022
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancerJinge Zhao, Guangxi Sun, Fengnian Zhao, et al.The Prostate|April 17, 2024
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67Fengnian Zhao, Jinge Zhao, Xinyuan Wei, et al.Quantitative Imaging in Medicine and Surgery|July 29, 2025
Predicting pathogenic DNA damage repair gene mutations in prostate cancer patients: a multi-center magnetic resonance imaging radiomics studyYuntian Chen, Jinge Zhao, Lei Ye, et al.Journal for Immunotherapy of Cancer|May 28, 2026
Pretreatment intratumoral mature TLSs in non-clear cell renal cell carcinoma are associated with response to immunotherapy rechallengeYanfeng Tang, Junru Chen, Jue Hu, et al.Journal of Cancer Research and Clinical Oncology|March 13, 2023
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancerNanwei Xu, Jinge Zhao, Fengnian Zhao, et al.Cancer Research|October 17, 2023
Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the ProstateJinge Zhao, Nanwei Xu, Sha Zhu, et al.Nature Communications|May 12, 2025
Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targetsXingming Zhang, Junjie Zhao, Xiaoxue Yin, et al.Pageof 9